Position in TNGX
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$32,416
-$1,516 QoQ
Shares Held
1,037
-36.1% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#213
of 247 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in TNGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ANTIPODES PARTNERS Ltd holds $60,434,232 across 11 Biotechnology names. TNGX ranks #8 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
163,533 | $49,228,338 | |
| 2 | HUMA |
Humacyte, Inc.
|
10,103,647 | $7,880,844 | |
| 3 | GPCR |
Structure Therapeutics Inc.
|
51,262 | $2,751,231 | |
| 4 | ARGX |
Argenx SE
|
187 | $173,492 | |
| 5 | IMNM |
Immunome Inc.
|
7,971 | $168,905 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
235 | $116,731 | |
| 7 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
379 | $36,944 | |
| 8 | TNGX |
Tango Therapeutics, Inc.
This page
|
1,037 | $32,416 |
All Filings in TNGX
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $32,416 | 1,037 | Shares | Sole | 2026-08-06 | |
| 2026-03-31 | $33,932 | 1,622 | Shares | Sole | 2026-05-05 | |
| 2025-12-31 | $39,985 | 4,513 | Shares | Sole | 2026-02-05 | |
| No filing history on record for this holder in this stock. | ||||||